In September, the US Food and Drug Administration approved Jansson for use in children aged 6-17 months.
The company has been working on an application for approval in the United Kingdom, which would enable it to be available for use by adults.
However, it has been unable to reach an agreement on this because of the United States’ regulatory regime.
While the US has been slow to accept Janssons drug for adults, it is expected that it will now be a long time before it is approved in the UK.
According to Dr Paul Rennie, president of the British Medical Association, the UK government is “a little bit behind” in this regard.
“It is certainly not a priority for the government.
It would be very hard to do that,” he said.
“There is a real fear that if we allow this to go forward in the short term it will create a new set of barriers to getting the drug approved.”
According the British Journal of Clinical Pharmacology, there is currently no evidence that Jansds drugs are more effective than those currently used for children.
Rennie said: “The evidence that we have on these drugs is very, very weak.
It is very hard for us to see that they are more useful for children than for adults.”
In January, it was reported that the US Department of Health and Human Services had received more than 40 applications for the Janssd drugs, many of which were for children aged under 6.
However, there was little evidence that the drugs are any more effective in treating children than other drugs, and the FDA has warned that Jamsden could “likely” delay approval of its drug.
Dr Peter Smith, a paediatrician at the University of Sheffield and former president of England’s National Health Service, said that the delays in Jansdens approval was “very worrying”.
“There is no doubt that this is an area that needs urgent attention,” he told Medscape Medical News.
“The fact that there is no agreement in the USA on how to proceed is very worrying, especially as it has had such a huge impact on the pharmaceutical industry.”
It is estimated that children aged between 6 and 13 are the biggest single target of the Jamsds drugs, but there has been no clear evidence that this has been exacerbated by the UK’s restrictive approach to drug approvals.
The latest figures from the British Pharmaceutical Association (BPAs) show that, as of the end of October, there were 4,939 approved Jamsd products, but only 10,068 applications for them.